WuXi PharmaTech (WX) Misses Q2 EPS by 1c, Reconfirms FY Rev Guidance

WuXi PharmaTech (NYSE: WX) reported Q2 EPS of $0.38, $0.01 worse than the analyst estimate of $0.39. Revenue for the quarter came in at $194.1 million versus the consensus estimate of $195.26 million.

Full-Year 2015 Financial Guidance

WuXi PharmaTech reconfirms full-year 2015 revenue guidance of $790-$800 million. The company withdraws its full-year 2015 guidance for GAAP and non-GAAP diluted EPS because of uncertainties regarding currency exchange-rate volatility and potential significant costs associated with several transactions under consideration. The rapid depreciation of the RMB against the U.S. dollar could result in significant mark-to-market losses and realized losses on foreign-exchange forward contracts.

For earnings history and earnings-related data on WuXi PharmaTech (WX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c